Navigation Links
NeuroPhage to Participate in World's First G8 Dementia Summit
Date:12/3/2013

CAMBRIDGE, Mass., Dec. 3, 2013 /PRNewswire/ -- NeuroPhage Pharmaceuticals, Inc. today announced that it has been invited to participate in the world's first G8 Dementia Summit. The G8 Summit is hosted by the British Prime Minister, David Cameron, and Health Secretary, Jeremy Hunt, and will be attended by G8 Health Ministers, pharmaceutical company leaders, innovators, technology pioneers, breakthrough researchers and investors. The Summit will explore the coordination of efforts to shape an effective international solution to dementia, a condition that affects over 35 million people worldwide, including looking for effective therapies to slow dementia's impact. The G8 Dementia Summit will take place in London, UK, on December 11, 2013.

"We applaud this groundbreaking initiative that the Prime Minister and the Health Secretary have undertaken to bring together leaders from government, research and finance to focus on addressing the enormous health and economic burden that dementia has on patients and families around the world," said Jonathan Solomon, President and Chief Executive Officer of NeuroPhage. "Dementia has proved to be a challenging indication to treat, as the biology behind the various conditions is complex. We are honored to take part in this ambitious international effort in hopes to create a greater collaborative approach worldwide to better achieve our common goals of treating and preventing dementia."

About NeuroPhage  

NeuroPhage Pharmaceuticals has fusion-protein drug candidates in development for neurodegenerative diseases, many of which cause progressive mental deterioration and dementia.  NeuroPhage's technology is based on a General Amyloid Interaction Motif (GAIM) that simultaneously targets multiple misfolded proteins or amyloids central to many neurodegenerative diseases such as Alzheimer's and Parkinson's diseases. In addition to targeting multiple misfolded pathological proteins, this unique disease-modifying approach recognizes early amyloid assemblies and existing protein aggregates to maximize potential therapeutic effect. NeuroPhage is initially developing candidates to treat Alzheimer's and Parkinson's disease, where a number of different misfolded proteins are present and their interactions can exacerbate disease progression.


'/>"/>
SOURCE NeuroPhage Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. NeuroPhage, Inc. Raises $6.4 Million In Additional Financing
2. Uroplasty To Participate In The Piper Jaffray Healthcare Conference
3. Hill-Rom to Participate in the 25th Annual Piper Jaffray Healthcare Conference
4. ProVen Pharmaceuticals Participates in the Dolphins Cycling Challenge
5. Boston Scientific To Participate In 2013 Credit Suisse Healthcare Conference
6. Inovio Pharmaceuticals to Participate in Immunotherapy Panel and Present at the 12th Annual BIO Investor Forum
7. Uroplasty To Participate In The Craig-Hallum Alpha Select Conference
8. montmed to participate in Vascular 2013
9. Questcor Pharmaceuticals to Participate in Morgan Stanley Global Healthcare Conference
10. Amgen To Participate At Citis 8th Annual Biotech Conference
11. China Biologic to Participate in Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... -- The primary goal of this research is to ... usage of liquid biopsy. Key information the survey seeks ... of liquid biopsy adoption amidst future users - Predominantly ... - Sample inflow to conduct liquid biopsy tests - ... so on. - Correlation analysis of sample type and ...
(Date:2/11/2016)... NEW YORK , Feb. 11, 2016 ... and instruments commonly used in laboratories. These may range ... scale condensers. Laboratory glassware is made from borosilicate glass ... shock. Laboratory plasticware, on the other hand, started gaining ... that it was easier to replace glass with plastic ...
(Date:2/11/2016)... , Feb. 11, 2016  Governor Andrew M. ... will create 1,400 jobs throughout Western New ... partnership with the SUNY Polytechnic Institute, includes a major ... Building in Buffalo , as well ... manufacturing facility in Dunkirk . The ...
Breaking Medicine Technology:
(Date:2/12/2016)... CA (PRWEB) , ... February 12, 2016 , ... As ... a hectic schedule, a demanding job, and no time to decompress, Rabinowitz found herself ... dedicated herself to meditation for its impact on her life, implementing a 20-minute-per-day meditation ...
(Date:2/12/2016)... ... February 12, 2016 , ... The ThedaCare Center ... Francisco General Hospital on April 5-7. The series is a multi-day, multi-workshop event ... The workshops cover a broad range of topics, including coaching skills, the scientific ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman and CEO Kenneth Fisher ... Military Support Alliance president Scott Bensing, and Peggy Kearns Director, VA Southern Nevada Healthcare ... System. This will be the first Fisher House in Nevada, and will provide ...
(Date:2/12/2016)... ... ... Vail knee specialist Robert LaPrade, MD, PhD was named one of ... of physicians establishing, leading and partnering with ambulatory surgery centers across the United States. ... also known as an ASC, is a modern health care facility focused on providing ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Donor Network West, ... California and Nevada, announced a partnership with San Ramon Regional Medical Center. Under the ... hospital’s facilities as a way to accommodate a more certain time frame for donor ...
Breaking Medicine News(10 mins):